Dendracin Neurodendraxcin

Description

Dendracin, also known as Neurodendraxcin®, is a topical pain relief lotion formulated for deep penetrating action. This product is presented in a 120 ml (4 fl oz) dosage form and is classified under the NDC 27495-014-04. The formulation is designed for professional use, providing effective relief for localized pain.

Uses and Indications

This drug is indicated for the temporary relief of mild pain associated with muscular strain, arthritis, and simple back pain. It is important to note that this drug does not cure any underlying disease.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The product should be used only as directed. Prior to the first application, it is recommended to rub a small amount on the skin to check for sensitivity. The product must be shaken well before each use. It should be gently rubbed over the painful areas, ensuring that the skin is dry before contact with clothing or bedding to prevent staining.

Healthcare professionals should advise patients to wash their hands thoroughly after each application. The product should not be used more than four times daily. Caution is advised for pregnant or nursing individuals, as the product is not recommended for use in these populations.

In the event of accidental ingestion, patients should contact poison control immediately. If the product comes into contact with the eyes, it is essential to rinse the eyes with cold water and seek medical attention.

Contraindications

Use of this product is contraindicated in the following situations:

Application on cuts or infected skin is prohibited due to the potential for exacerbating the condition. The product should not be used in children under 12 years of age, as safety and efficacy have not been established in this population. Additionally, the use of large amounts, particularly over raw or blistered skin, is contraindicated to prevent adverse effects. Finally, individuals with known allergies to any ingredients in the formulation, including PABA, aspirin products, or sulfa, should avoid use to prevent allergic reactions.

Warnings and Precautions

For external use only, this product must not be applied to the eyes, mouth, mucous membranes, or genital areas. It is imperative to avoid tightly bandaging the treated area and to refrain from using it in conjunction with heating pads or other topical pain products.

Caution is advised when using this product. It should not be applied to cuts or infected skin, nor should it be used on children under 12 years of age. Application in large amounts, particularly over raw or blistered skin, is contraindicated. Individuals with known allergies to any ingredients, including PABA, aspirin products, or sulfa, should avoid use.

Healthcare professionals should instruct patients to discontinue use and seek medical advice if they experience severe undiagnosed pain, if pain worsens or persists beyond 7 days, or if pain resolves only to recur within a few days. Additionally, patients should be advised to consult a physician if they develop itching or a rash following application.

No specific emergency medical help instructions or laboratory tests are provided; however, practitioners should remain vigilant for any adverse reactions and manage them accordingly.

Side Effects

Patients using this product may experience a range of adverse reactions. It is important to note that the product is intended for external use only and should not be applied to the eyes, mouth, mucous membranes, or genital areas. Additionally, patients should avoid tightly bandaging the area of application, using the product in conjunction with a heating pad, or combining it with other topical pain products.

In the event of severe undiagnosed pain, or if the pain worsens or persists for more than 7 days, patients are advised to discontinue use and consult a physician. Furthermore, if pain resolves and then recurs within a few days, or if any itching or rash occurs, medical advice should be sought promptly. These precautions are essential to ensure patient safety and to mitigate the risk of potential adverse effects.

Drug Interactions

Co-administration of this product with other topical pain products is not recommended. The concurrent use may increase the risk of adverse effects without providing additional therapeutic benefit. It is advisable to avoid such combinations to ensure patient safety and optimal therapeutic outcomes.

Packaging & NDC

Below are the non-prescription pack sizes of Dendracin Neurodendraxcin (methyl salicylate, menthol and capsaicin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not be administered this medication. Safety and efficacy have not been established in this population, and use in younger children is contraindicated. Healthcare professionals are advised to consider alternative treatments for this age group.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should not use this medication more than four times daily. The safety of this medication during pregnancy has not been established, and its use is not recommended in pregnant or nursing women. Healthcare professionals should weigh the potential benefits against the risks when considering treatment options for women of childbearing potential.

Lactation

Lactating mothers are advised against the use of this medication while nursing. There is no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, the potential risks to the nursing infant outweigh any possible benefits of treatment in lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, the following management procedures should be considered:

1. Assessment: Conduct a thorough assessment of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide supportive care as needed, which may include airway management, oxygen supplementation, and intravenous fluids.

3. Consultation: Engage with a poison control center or toxicology expert for guidance on specific interventions and antidotes, if applicable.

4. Documentation: Document all findings, interventions, and the patient's response to treatment meticulously.

Healthcare professionals should remain vigilant and prepared to implement these general management strategies in the event of an overdose, even in the absence of specific overdosage information.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse. It is important to inform patients about specific situations in which they should not use the product. Patients should be instructed not to apply the medication on cuts or infected skin, on children under 12 years of age, or in large amounts, particularly over raw or blistered skin. Additionally, patients should be cautioned against using the product if they have a known allergy to any of its ingredients, including PABA, aspirin products, or sulfa.

Patients should be informed about the proper storage conditions for the medication, emphasizing that it should be kept below 90°F (32°C) to maintain its efficacy.

Healthcare providers should also instruct patients to stop using the medication and seek medical advice if they experience severe undiagnosed pain, if their pain worsens or persists for more than 7 days, if the pain resolves and then recurs within a few days, or if they develop itching or a rash. This guidance is essential to ensure patient safety and effective use of the medication.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a controlled environment, maintaining a temperature below 90°F (32°C) to ensure its stability and efficacy. Proper storage conditions are critical to preserving the integrity of the product throughout its shelf life.

Additional Clinical Information

The product is administered topically and should be used only as directed, with a maximum frequency of four applications per day. It is contraindicated for use in pregnant or nursing individuals. Prior to initial application, patients are advised to rub a small amount on the skin to check for sensitivity. The product should be gently rubbed over painful areas, and it is important to allow the area to dry before coming into contact with clothing or bedding to prevent staining. Patients should wash their hands after use, and in case of accidental ingestion, they should contact poison control. If the product comes into contact with the eyes, it is recommended to rinse with cold water and seek medical attention.

Drug Information (PDF)

This file contains official product information for Dendracin Neurodendraxcin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)